Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.

Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.

Item
http://www.wikidata.org/entity/Q37627015
Non-invasive diagnosis of liver fibrosis in chronic hepatitis CLong-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established BiomarkersThe natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon.Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B
P2860

Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.

Item
http://www.wikidata.org/entity/Q37627015
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of the aspartate am ...... is due to chronic hepatitis C.
@en
Evaluation of the aspartate am ...... is due to chronic hepatitis C.
@nl
type
label
Evaluation of the aspartate am ...... is due to chronic hepatitis C.
@en
Evaluation of the aspartate am ...... is due to chronic hepatitis C.
@nl
prefLabel
Evaluation of the aspartate am ...... is due to chronic hepatitis C.
@en
Evaluation of the aspartate am ...... is due to chronic hepatitis C.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Evaluation of the aspartate am ...... is due to chronic hepatitis C.
@en
P2093
P2860
P304
P31
P356
10.1097/MCG.0B013E3182A87E78
P433
P478
P50
P577
P698
P932